Intellia Therapeutics faces March FDA decision for one-time CRISPR HAE therapy
Intellia faces a March 10 FDA decision for lonvo-z after one CRISPR infusion cut HAE attacks 87% in Phase 3 testing.
Pharma & Biotech
Pharma & Biotech
Why Intellia’s lonvo-z Phase 3 data could raise expectations for one-time HAE treatment
Find out how Intellia’s lonvo-z Phase 3 data could change expectations for one-time hereditary angioedema treatment.